CompletedNCT00892580

Biomarker and DNA Collection in Subjects Participating in Protocol 22003

Studying Fragile X syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Seaside Therapeutics, Inc.
Principal Investigator
Craig Erikson, MD
Riley Hospital for Children
Intervention
STX209(drug)
Enrollment
32 enrolled
Eligibility
6-17 years · All sexes
Timeline
2009

Study locations (8)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00892580 on ClinicalTrials.gov

Other trials for Fragile X syndrome

Additional recruiting or active studies for the same condition.

See all trials for Fragile X syndrome

← Back to all trials